- NCIt
- C4107
Loading cancer entity…
Loading cancer entity…
Clinical trials
30 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | suspended | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 3 | Sep 1, 2026 |
| clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT06969534 | Safety and Efficacy of Pucotenlimab in pLECC | recruiting | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT01956084 | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma(ALCI2) | completed | Phase 1 | 10 | Catherine BollardOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04614818 | A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma | unknown | — | 700 | Sun Yat-sen UniversityOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04430166 | PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma | unknown | N/A | 12 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma(ALCI) | completed | Phase 1 | 74 | Baylor College of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00408694 | Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2018 | clinicaltrials |
| NCT00454142 | Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer | terminated | N/A | 7 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01155609 | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer | completed | N/A | 10 | University of WashingtonOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00023959 | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00068497 | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | completed | N/A | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT01637194 | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | completed | Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
Data updated 13 hours agoSource updated Sep 29, 2026source: clinicaltrials